Drug-eluting versus bare-metal stents for treating saphenous vein grafts

American Heart Journal

Volumn 158, Issue 4, 2009, Pages 637-643

  Shishehbor, Mehdi H ^a   Hawi, Riem ^a   Singh, Inder M ^b   Tuzcu, E Murat ^a   Bhatt, Deepak L ^c   Ellis, Stephen G ^a   Kapadia, Samir R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARE METAL STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SAFETY; VEIN GRAFT DISEASE;

AGED; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; INCIDENCE; MALE; MYOCARDIAL REVASCULARIZATION; RETROSPECTIVE STUDIES; SAPHENOUS VEIN; TREATMENT OUTCOME; UNITED STATES;

EID: 70349216489     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.08.003     Document Type: Article

References (38)

1. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 51 (2008) 172-209
2. Baim D.S. Percutaneous treatment of saphenous vein graft disease: the ongoing challenge. J Am Coll Cardiol 42 (2003) 1370-1372
3. de Feyter P.J. Percutaneous treatment of saphenous vein bypass graft obstructions: a continuing obstinate problem. Circulation 107 (2003) 2284-2286
4. Brilakis E.S., Saeed B., and Banerjee S. Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: a critical appraisal. J Interv Cardiol 21 (2008) 151-157
5. Vermeersch P., Agostoni P., Verheye S., et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 48 (2006) 2423-2431
6. Vermeersch P., Agostoni P., Verheye S., et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 50 (2007) 261-267
7. Brilakis E.S., Lichtenwalter C., de Lemos J.A., et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 53 (2009) 919-928
8. Blankenship J.C. Parsing the subsets: when small studies create confusion. Catheter Cardiovasc Interv 72 (2008) 23-24
9. Colombo A., and Chieffo A. Drug-eluting stent update 2007: part III: technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease). Circulation 116 (2007) 1424-1432
10. Morrison D.A., Sethi G., Sacks J., et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 40 (2002) 1951-1954
11. Savage M.P., Douglas Jr. J.S., Fischman D.L., et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 337 (1997) 740-747
12. Brilakis E.S., and Berger P.B. Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?. Catheter Cardiovasc Interv 72 (2008) 815-818
13. Hanekamp C.E., Koolen J.J., Den Heijer P., et al. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: the Venestent study. Catheter Cardiovasc Interv 60 (2003) 452-457
14. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
15. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
16. Jeger R.V., Schneiter S., Kaiser C., et al. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology 112 (2009) 49-55
17. Assali A., Raz Y., Vaknin-Assa H., et al. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. EuroIntervention 4 (2008) 108-114
18. Kaplan S., Barlis P., Kiris A., et al. Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. Acute Card Care 10 (2008) 88-92
19. Minutello R.M., Bhagan S., Sharma A., et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 20 (2007) 458-465
20. Hoffmann R., Pohl T., Koster R., et al. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart 93 (2007) 331-334
21. Wohrle J., Nusser T., Kestler H.A., et al. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 96 (2007) 70-76
22. Lee M.S., Shah A.P., Aragon J., et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 66 (2005) 507-511
23. Ge L., Iakovou I., Sangiorgi G.M., et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 45 (2005) 989-994
24. Lozano I., Garcia-Camarero T., Carrillo P., et al. Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results. Rev Esp Cardiol 62 (2009) 39-47
25. van Twisk P.H., Daemen J., Kukreja N., et al. Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts. EuroIntervention 4 (2008) 311-317
26. Okabe T., Lindsay J., Buch A.N., et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol 102 (2008) 530-534
27. Gioia G., Benassi A., Mohendra R., et al. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 72 (2008) 13-20
28. Applegate R.J., Sacrinty M., Kutcher M., et al. Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: propensity score analysis. Catheter Cardiovasc Interv 72 (2008) 7-12
29. Ramana R.K., Ronan A., Cohoon K., et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv 71 (2008) 886-893
30. Vignali L., Saia F., Manari A., et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). Am J Cardiol 101 (2008) 947-952
31. Bansal D., Muppidi R., Singla S., et al. Percutaneous intervention on the saphenous vein bypass grafts-long-term outcomes. Catheter Cardiovasc Interv 71 (2008) 58-61
32. Ellis S.G., Kandzari D., Kereiakes D.J., et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol 19 (2007) 404-409
33. Chu W.W., Rha S.W., Kuchulakanti P.K., et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 97 (2006) 34-37
34. Holmes Jr. D.R., Kereiakes D.J., Laskey W.K., et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol 50 (2007) 109-118
35. Christiansen J.F., Hartwig D., Bechtel J.F., et al. Diseased vein grafts express elevated inflammatory cytokine levels compared with atherosclerotic coronary arteries. Ann Thorac Surg 77 (2004) 1575-1579
36. Ellis S.G., Brener S.J., DeLuca S., et al. Late myocardial ischemic events after saphenous vein graft intervention-importance of initially "nonsignificant" vein graft lesions. Am J Cardiol 79 (1997) 1460-1464
37. Keeley E.C., Velez C.A., O'Neill W.W., et al. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 38 (2001) 659-665
38. Pache J., Kastrati A., Mehilli J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41 (2003) 1283-1288